EXACT Sciences Co. (NASDAQ:EXAS) was down 8.1% during mid-day trading on Wednesday . The company traded as low as $75.78 and last traded at $75.94. Approximately 2,058,037 shares changed hands during mid-day trading, an increase of 47% from the average daily volume of 1,400,555 shares. The stock had previously closed at $82.66.
A number of equities research analysts have issued reports on EXAS shares. UBS Group started coverage on shares of EXACT Sciences in a research report on Tuesday, October 9th. They issued a “buy” rating and a $100.00 target price for the company. Canaccord Genuity increased their target price on shares of EXACT Sciences from $72.00 to $87.00 and gave the stock a “buy” rating in a research report on Wednesday, September 12th. BidaskClub downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. BTIG Research increased their target price on shares of EXACT Sciences to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Finally, Zacks Investment Research upgraded shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 30th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $84.08.
The stock has a market capitalization of $9.58 billion, a PE ratio of -76.71 and a beta of 1.20. The company has a current ratio of 12.08, a quick ratio of 11.72 and a debt-to-equity ratio of 0.94.
EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. The business had revenue of $118.29 million for the quarter, compared to the consensus estimate of $109.33 million. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. EXACT Sciences’s revenue for the quarter was up 63.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.23) EPS. On average, sell-side analysts expect that EXACT Sciences Co. will post -1.5 earnings per share for the current year.
In other news, insider Kevin T. Conroy sold 163,514 shares of the firm’s stock in a transaction on Monday, November 12th. The shares were sold at an average price of $69.00, for a total transaction of $11,282,466.00. Following the transaction, the insider now owns 886,011 shares in the company, valued at approximately $61,134,759. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Graham Peter Lidgard sold 79,673 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $71.73, for a total transaction of $5,714,944.29. Following the transaction, the insider now owns 124,528 shares in the company, valued at approximately $8,932,393.44. The disclosure for this sale can be found here. Insiders have sold a total of 386,968 shares of company stock worth $27,418,499 in the last 90 days. 3.20% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Cornerstone Wealth Management LLC bought a new position in shares of EXACT Sciences during the 2nd quarter valued at $182,000. Chicago Partners Investment Group LLC raised its holdings in shares of EXACT Sciences by 47.6% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,100 shares of the medical research company’s stock valued at $191,000 after purchasing an additional 1,000 shares in the last quarter. First Republic Investment Management Inc. bought a new position in shares of EXACT Sciences during the 3rd quarter valued at $204,000. Fulton Bank N.A. bought a new position in shares of EXACT Sciences during the 3rd quarter valued at $208,000. Finally, Alps Advisors Inc. bought a new position in shares of EXACT Sciences during the 2nd quarter valued at $210,000. Institutional investors and hedge funds own 92.25% of the company’s stock.
TRADEMARK VIOLATION WARNING: “EXACT Sciences (EXAS) Stock Price Down 8.1%” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/12/06/exact-sciences-exas-stock-price-down-8-1.html.
About EXACT Sciences (NASDAQ:EXAS)
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Read More: Trading Penny Stocks
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.